Using Blinatumomab for treating relapsed Acute B-cell Lymphoblastic Leukemia after transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the efficacy and safety of Blinatumomab in patients with relapsed Acute B-cell Lymphoblastic Leukemia (B-ALL) following allogeneic hematopoietic stem cell transplantation. Patients who experience a relapse will receive Blinatumomab treatment, followed by donor lymphocyte infusion (DLI) to enhance the anti-leukemic effect. The study aims to analyze the outcomes and side effects associated with this sequential treatment approach. Enrollment is open for patients aged 65 and younger who meet specific health criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≤65 years old
2. Stable vital signs
3. No severe infection
4. There was no grade II-IV graft-versus-host disease
5. No organ failure

Exclusion Criteria:

1. Age \> 65 years old
2. Unstable vital signs
3. Complicated with severe infection
4. Combined with grade Ⅱ-Ⅳ graft-versus-host disease
5. Heart, liver, kidney and other organ failure
6. Complicated with central nervous system leukemia
7. Allergies to medications in the treatment regimen

Where it's running

• The First Affiliated Hospital of Zhengzhou University
  Zhenzhou, Henan, China Recruiting

Study contacts

• Principal investigator: Zhilei BIAN — The First Affiliated Hospital of Zhengzhou University
• Study coordinator: Suping ZHANG
• Email: zsp198612@163.com
• Phone: +8613523510641

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blinatumomab plus low-dose donor cells after transplant for high-risk B-ALL

  This small, early-phase study tests whether giving blinatumomab with low-dose donor lymphocytes after allogeneic transplant is safe and helps long-term survival for people with high-risk B-ALL.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07677878

• LP-118 in combination with standard therapy for newly diagnosed Ph+ ALL

  This study tests whether adding LP-118 to the standard therapy for adults with Philadelphia chromosome–positive ALL is safe and useful.

  Recruiting at 2 sites Phase 1 Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT07614022

• MK-1045 versus blinatumomab for relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia

  This trial will test whether MK-1045 helps people with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia more than the standard immunotherapy blinatumomab.

  Recruiting at 30 sites Phase 2/3 Merck Sharp & Dohme LLC · Toronto, Ontario and 29 other locations · NCT07570173

• Vaccine protection after blinatumomab in children with B-ALL

  This project will see if children and young adults (ages 1–21) with B-cell acute lymphoblastic leukemia who received blinatumomab keep protective immunity from routine childhood vaccines and whether revaccination restores immunity when levels are low.

  Recruiting at 2 sites Arkansas Children's Hospital Research Institute · Little Rock, Arkansas and 1 other locations · NCT07422337

• Asciminib in children and young adults with relapsed or refractory Ph+ or ABL-class Ph-like ALL

  This study tests asciminib in kids and young adults with relapsed or refractory Philadelphia-positive or ABL-class Ph-like ALL to see if it is safe and helps treat the leukemia.

  Recruiting at 4 sites Phase 1/2 Novartis · Sydney, New South Wales and 3 other locations · NCT07387926

• Subcutaneous blinatumomab treatment for adults with CD19-positive mixed phenotype acute leukemia

  This trial tests whether giving blinatumomab under the skin can help adults with CD19-positive mixed phenotype acute leukemia, including older or unfit newly diagnosed patients, those with measurable residual disease after remission, and those with relapsed or refractory disease.

  Recruiting Phase 2 West Virginia University · Morgantown, West Virginia · NCT07222579

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.